drugset
Drugs / ABP 980
last change Mar 2020 re-read 2 minutes ago

ABP 980

also known as KANJINTI
Developed for
female breast carcinoma
Investigated by
Actavis Inc. · Amgen

Trials 1 · a red edge is where a trial was stopped

today NCT01901146 · Ph 3
201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 3 NCT01901146 Apr 2013 → May 2016 female breast carcinoma Amgen Completed No outcome recorded

Press releases naming this drug 6 releases

DateIssuerRelease
2019-07-19 Amgen Amgen And Allergan's MVASI™ (bevacizumab-awwb) And KANJINTI™ (trastuzumab-anns) Now Available In The United States amgen.com ↗
2019-06-13 Amgen FDA Approves Amgen And Allergan's KANJINTI™ (trastuzumab-anns), A Biosimilar To Herceptin® (trastuzumab) amgen.com ↗
2018-03-23 Amgen Amgen And Allergan Receive Positive CHMP Opinion For ABP 980 (Biosimilar Herceptin®) For The Treatment Of Three Types Of Cancer amgen.com ↗
2017-09-09 Amgen Amgen And Allergan Present Phase 3 Data On Biosimilar Trastuzumab Candidate ABP 980 At The European Society For Medical Oncology 2017 Congress amgen.com ↗
2017-07-31 Amgen Amgen And Allergan Submit Biosimilar Biologics License Application For ABP 980 To US Food And Drug Administration amgen.com ↗
2016-07-21 Amgen Amgen And Allergan Announce Top-Line Results From Phase 3 Study Evaluating ABP 980 Compared With Trastuzumab In Patients With Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer amgen.com ↗

Evidence & citations 3 cited values

Every value below carries the sentence it was read from. 2 sources stand behind the page.

FieldValueCited text
Known as ABP 980 ClinicalTrials.gov intervention name — accepted as the source's own label NCT01901146 ↗
Known as KANJINTI “OBJECTIVE: In this prespecified analysis, we compared the cardiac safety of the trastuzumab biosimilar ABP 980 (KANJINTI™) and the trastuzumab reference product (RP;...” PMID 31927716 ↗ Mar 2020
Route Intravenous “ABP 980 was administered at an initial dose of 8 mg/kg over a 90-minute intravenous (IV) infusion, then 6 mg/kg IV infusion Q3W for all subsequent cycles.” NCT01901146 ↗